Biopharma Credit Investments V (master) LP
Private Equity FundFund ID 805-2616755366Cayman Islands
Gross assets
$1.87B
Min. investment
—
Beneficial owners
171
Size rank
Top 4%
Audited
Yes
Structure
Master
About this fund
Biopharma Credit Investments V (master) LP is a private equity fund managed by Pharmakon Advisors, LP. The fund reports $1.9 billion in gross assets, placing it among the top 4% of private funds by size. Its financial statements are audited annually. Private funds are not required to publicly disclose returns; Form ADV reports assets, structure, and service providers, shown above.
Fund details
| Fund ID | 805-2616755366 |
| Fund type | Private Equity Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | Yes |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| % of assets independently valued | 0% |
Other funds from this manager
None reported.
Frequently asked questions
How large is Biopharma Credit Investments V (master) LP?
Biopharma Credit Investments V (master) LP reports $1.9 billion in gross assets, among the top 4% of private funds by size.
Who manages Biopharma Credit Investments V (master) LP?
Biopharma Credit Investments V (master) LP is managed by Pharmakon Advisors, LP.
Does Biopharma Credit Investments V (master) LP disclose returns?
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.
Manager
P
New York, NY
Service providers
Prime broker
None reported
Custodian
Administrator
Auditor
Marketer
Reported gross assets
$1.87B▲ 10%
Mar '25Form ADV, monthlyJun '26
How this fund compares
Gross assetsTop 4%
Larger than 96% of 67,041 private funds
Gross assets vs Private Equity FundsTop 3%
Larger than 97% of 31,066 private equity funds
Investor base
Adviser & related persons1%
Funds of funds13%
Non-U.S. persons22%
Share of the fund's beneficial ownership reported on Form ADV. Categories can overlap.